Douglas Earl Martin 4
4 · Allogene Therapeutics, Inc. · Filed Jan 31, 2024
Insider Transaction Report
Form 4
Douglas Earl Martin
SVP, General Counsel
Transactions
- Award
Stock Option (Right to buy)
2024-01-25+147,778→ 147,778 totalExercise: $3.20Exp: 2034-01-25→ Common Stock (147,778 underlying) - Award
Common Stock
2024-01-25+41,800→ 477,634 total
Footnotes (1)
- [F1]1/3 of the shares subject to the stock option shall vest on January 25, 2025, and the remaining shares shall vest in 24 equal monthly installments thereafter.